Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Instituto Mexicano del Seguro Social, Ente Ospedaliero Ospedali Galliera

Conditions

Antiretroviral TreatmentHIV 1 InfectionHIV InfectionHealthyMetabolic Syndrome

Phase 1

A Study of JNJ-56136379 in Healthy Participants

WithdrawnNCT04853524

Janssen Research & Development, LLCHealthy

Start: 2021-05-06End: 2021-07-30Updated: 2021-07-15

Phase 4

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

RecruitingNCT07031063

Instituto Mexicano del Seguro SocialAntiretroviral Treatment, HIV Infection, Metabolic Syndrome

Start: 2025-04-01End: 2028-12-01Target: 124Updated: 2025-06-26

Unknown Phase

Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO).

Not yet recruitingNCT07859904

Ente Ospedaliero Ospedali GallieraHIV 1 Infection

Start: 2026-12-15End: 2028-01-31Target: 100Updated: 2026-10-09